In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).

Key Clinical Trials Discussed

1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL

2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL

3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)

4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL

5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL

6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL

7. Additional Studies Mentioned:

R-Pola-Glo Frail Study

DLBCL Classification